25 To 99 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.3)
-
Patent number: 8586533Abstract: A method for treating early-stage osteoarthritis in an animal is provided. The method comprises delivery of a therapeutically effective amount of a parathyroid hormone (PTH) or a PTH derived substance to an affected joint cavity of the patient. Methods for inhibiting articular chondrocytes apoptosis and for inhibiting a degenerative process of articular chondrocytes in an afflicted animal are also provided.Type: GrantFiled: December 15, 2009Date of Patent: November 19, 2013Assignee: Kaohsiung Medical UniversityInventors: Mei-Ling Ho, Gwo-Jaw Wang, Je-Ken Chang, Yin-Chih Fu, Chung-Hwan Chen
-
Patent number: 8580731Abstract: An insulin-gold nanocluster, a pharmaceutical composition for treating diabetes comprising the insulin-gold nanocluster, and a method for detecting adipose cells in a tissue by using the insulin-gold nanocluster are provided. Herein, the insulin-gold nanocluster of the present invention comprises: a gold nanocluster, and insulin connecting to the gold nanocluster, wherein the insulin-gold nanocluster emits red fluorescence at maximized wavelength of 670 nm.Type: GrantFiled: February 17, 2012Date of Patent: November 12, 2013Assignee: National Taiwan UniversityInventors: Pi-Tai Chou, Chien-Liang Liu, Yun-Chen Chien
-
Patent number: 8580738Abstract: The present invention discloses methods to prevent and treat cardiovascular disorders, hi certain aspects the methods are drawn to releasing endogenous calcitonin-gene related peptide from intrinsic cardiac adrenergic cells within the heart. In further aspects, a combination of a ?2 adrenergic receptor agonist (?2-AR agonist) and a vasodilator can be used in treating reperfusion injury.Type: GrantFiled: April 30, 2008Date of Patent: November 12, 2013Assignee: The Board of Regents of the University of Texas SystemInventors: Ming-He Huang, Yochai Birnbaum, Barry F. Uretsky
-
Publication number: 20130296260Abstract: An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient.Type: ApplicationFiled: January 12, 2012Publication date: November 7, 2013Applicant: University of MiyazakiInventors: Kazuo Kitamura, Shinya Ashizuka, Haruhiko Inatsu, Toshihiro Kita
-
Publication number: 20130296225Abstract: The disclosure provides microcrystals of Y receptor agonists; microcrystalline pellets of Y receptor agonists, and microcrystalline suspensions of Y receptor agonists. Pharmaceutical compositions containing these microcrystals, microcrystalline pellets, and microcrystalline suspensions have prolonged pharmacokinetic profiles making them useful for once daily or once weekly administration.Type: ApplicationFiled: July 8, 2011Publication date: November 7, 2013Applicant: Amylin Pharmaceuticals LLCInventor: Steven Shijun Ren
-
Patent number: 8575110Abstract: Described is a new type of nanoparticle using the concept of self-organization of a single continuous chain to form peptidic nanoparticles. In particular, nanoparticles of the invention consist of aggregates of a continuous chain comprising two peptidic oligomerization domains connected by a linker segment. Preferred are coiled-coil oligomerization domains with a contiguous pattern of hydrophobic residues spaced 3 and 4 residues apart. The invention provides a drug targeting and delivery system comprising a functionalized peptidic nanoparticle comprising ligands capable of binding a receptor and drugs, and a method of treating or diagnosing humans using such functionalized peptidic nanoparticles. The invention further provides an antigen display system to be used as efficient vaccines comprising a functionalized peptidic nanoparticle comprising an antigen, and a method of vaccinating humans or non-human animals using such functionalized peptidic nanoparticles.Type: GrantFiled: February 16, 2004Date of Patent: November 5, 2013Assignee: Alpha-O Peptides GInventor: Peter Burkhard
-
Patent number: 8575096Abstract: The invention is related to fast acting insulin analogues which can form soluble mix-tures (pre-mixed or self-mixed) with long acting insulin analogues. The fast action is achieved through monomerizing substitutions/deletions in the C-terminus of the B-chain of human insulin and the mixability with long acting insulin analogues is achieved through a substitution of the Zn-binding His in position B10 of human insulin with a Gln amino acid residue. In one embodiment the invention is related to fast acting insulin analogues in which at least one of the natural amino acid residues in position B22-B30 in the human B-chain has been substituted with another amino acid residue having the effect of promoting formation of the monomeric form of insulin, the His amino acid residue in position 10 in the B-chain is substituted with a Gln and wherein further one or more of the amino acid residues in position B22-B30 optionally have been deleted.Type: GrantFiled: August 12, 2008Date of Patent: November 5, 2013Assignee: Novo Nordisk A/SInventors: Helle Birk Olsen, Thomas Børglum Kjeldsen, Per Balschmidt, Tine Glendorf, Svend Havelund
-
Patent number: 8574584Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.Type: GrantFiled: January 20, 2012Date of Patent: November 5, 2013Assignee: University of Pittsburgh —of the Commonwealth System of Higher EducationInventors: Walter J. Storkus, Michael S. Klnch
-
Patent number: 8575105Abstract: The present invention relates to the use of an Engrailed transcription factor for producing a medicament for anxiolytic purposes.Type: GrantFiled: February 28, 2007Date of Patent: November 5, 2013Assignee: Centre National de la Recherche ScientifiqueInventors: Alain Prochiantz, Michel Volovitch
-
Patent number: 8575305Abstract: The present invention discloses cell penetrating peptides and conjugates of a cell penetrating peptide and a cargo molecule.Type: GrantFiled: May 15, 2009Date of Patent: November 5, 2013Assignee: Medical Research CouncilInventors: Michael John Gait, Andrey Alexandrovich Arzumanov, Gabriela Dimitroval Ivanova
-
Publication number: 20130288964Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.Type: ApplicationFiled: March 14, 2013Publication date: October 31, 2013Inventors: Johannes Gerhardus Maria Bolscher, Arie van Nieuw Amerongen, Engelmundus Cornelis Ignatius Veerman, Menno Johannes Oudhoff, Willem van't Hof, Kamran Nazmi, Petronella Adriana Maria van den Keijbus
-
Patent number: 8569447Abstract: The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.Type: GrantFiled: July 20, 2012Date of Patent: October 29, 2013Assignee: Xigen SAInventor: Christophe Bonny
-
Patent number: 8569240Abstract: The present invention relates to methods for preventing or treating neurological diseases, particularly brain diseases, and improving cognitive functions using a composition comprising stanniocalcin 2 as an active ingredient.Type: GrantFiled: August 14, 2011Date of Patent: October 29, 2013Assignee: Regeron, Inc.Inventors: Heejae Lee, Jong-Seon Byun, Kyung Young Lee, Dahlkyun Oh
-
Patent number: 8569229Abstract: Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.Type: GrantFiled: August 9, 2010Date of Patent: October 29, 2013Assignee: The Children's Hospital of PhiladelphiaInventor: Michael M. Grunstein
-
Patent number: 8569226Abstract: A dodecamer peptide, and its modified variant, having a repeating glycine-lysine sequence was created and found to bind with high affinity to oxide surfaces and certain activated polymeric surfaces. Reversible binding characteristics of the peptides were demonstrated. The peptides were integrated with proteins, cells and fusion proteins to provide attachment of the proteins, cells and fusion proteins to solid material structures. The peptides can be used to functionalize surfaces of components within mechanical, in mechanical, biomechanical, micro fluidic, electronic, bioelectronic, bio-optical, and biochemical devices. Experiments were carried out to assess functionalization and reusability of a suspended mass resonator's cantilever.Type: GrantFiled: September 19, 2008Date of Patent: October 29, 2013Assignee: Massachusetts Institute of TechnologyInventors: Eric Mark Krauland, Stephen Kottmann, Roberto Juan Barbero, Angela Belcher
-
Publication number: 20130281383Abstract: The invention relates to novel uses of the polypeptide elafin, and/or homologies, derivatives or fragments thereof having inhibitory activity against leukocyte elastase for the prevention and treatment of medical conditions like SIRS.Type: ApplicationFiled: March 2, 2011Publication date: October 24, 2013Applicant: PROTEO BIOTECH AGInventors: Oliver Wiedow, Birge Bargmann, Barbara Kahlke, Lee Shaw, Nils Wichmann
-
Patent number: 8563513Abstract: Provided herein are Parathyroid hormone (PTH) peptides and parathyroid hormone-related protein (PTHrP) peptides (e.g., PTH analogs, PTHrP analogs), and related variants, chemical derivatives, fusion polypeptides, multimeric polypeptides, and peptidomimetics, peptoids, the like. Also provided are their use in methods for activating the PTH receptor in a cell (e.g., an osteoblast), methods of treating a subject with bone loss (e.g., by administration of a PTH peptide or PTHrP peptide (e.g., a PTH analog or PTHrP analog)), methods of ameliorating a symptom associated with osteoporosis in a subject, methods of retarding the progression of osteoporosis in a subject, and methods of regenerating bone in a subject.Type: GrantFiled: March 26, 2010Date of Patent: October 22, 2013Assignees: Van Andel Research Institute, The General Hospital CorporationInventors: Huaqiang Eric Xu, Augen A. Pioszak, Thomas J. Gardella
-
Patent number: 8563683Abstract: The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed.Type: GrantFiled: July 20, 2007Date of Patent: October 22, 2013Assignees: University of Rochester, The Los Angeles BioMedical Research Institute at Harbor—UCLA Medical Center, University of GuelphInventors: Robert H. Notter, Zhengdong Wang, Adrian L. Schwan, Zhongyi Wang, Jason A. Davy, Alan J. Waring, Frans J. Walther, Larry M. Gordon
-
Patent number: 8563514Abstract: Provided is a pharmaceutical composition for sequestering cells in connective tissue. The composition includes a biocompatible scaffolding to which one or more peptides or proteins are linked. The peptides or proteins have an amino acid sequence that is a subsequence of human ficolin and are capable of binding the cells to be sequestered. The pharmaceutical composition can be used in the treatment of connective tissue, and can be used as a dermal filler.Type: GrantFiled: August 14, 2008Date of Patent: October 22, 2013Assignee: MetamorefixInventors: Mazal Dahan, Raphael Gorodetsky
-
Patent number: 8563521Abstract: Increased in vivo and/or in vitro stability is imparted to a biologically active protein by fusing to an amino acid sequence consisting of at least about 100 amino acid residues, which are Alanine, Serine and Proline, which form a random coil conformation. Specific examples are described. Also described are related nucleic acids, vectors and cells encoding such amino acids; compositions of biologically active proteins fused to a random coil domain, and methods of making and using the compounds and compositions of the invention.Type: GrantFiled: June 20, 2008Date of Patent: October 22, 2013Assignee: Technische Universitat MunchenInventors: Arne Skerra, Ina Theobald, Martin Schlapschy
-
Publication number: 20130274202Abstract: The present invention relates to peptide from 4 to 50 amino acids comprising a phosphorylated pYX1X2X1 motif (SEQ ID NO: 1), wherein each X1 independently is M or Nle and X2 is any amino acid, pharmaceutical compositions comprising said peptide and use thereof for treating cancer.Type: ApplicationFiled: December 12, 2011Publication date: October 17, 2013Applicant: GENE SIGNAL INTERNATIONAL SAInventors: Salman Al-Mahmood, Sylvie Colin
-
Publication number: 20130274206Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.Type: ApplicationFiled: March 15, 2013Publication date: October 17, 2013Applicant: MUSC Foundation for Research DevelopmentInventor: MUSC Foundation for Research Development
-
Patent number: 8551946Abstract: Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided.Type: GrantFiled: January 26, 2011Date of Patent: October 8, 2013Assignee: Indiana University Research and Technology CorporationInventors: Richard D. Dimarchi, Tao Ma
-
Publication number: 20130259907Abstract: The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. Typically, the composition is not an emulsion, but has a low viscosity and further provides for minimized initial burst and sustained release of the beneficial agent over time. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition.Type: ApplicationFiled: March 7, 2013Publication date: October 3, 2013Inventors: William van Osdol, Su Il Yum, Felix Theeuwes, Michael Sekar, John W. Gibson, Keith E. Branham, Huey-Ching Su
-
Publication number: 20130261053Abstract: Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions.Type: ApplicationFiled: April 2, 2013Publication date: October 3, 2013Applicants: ServicesInventor: The United States of America, as represented by the Secretary, Department of Health and Human Services
-
Patent number: 8546327Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).Type: GrantFiled: June 16, 2009Date of Patent: October 1, 2013Assignee: Indiana University Research and Technology CorporationInventors: Richard D. Dimarchi, David L. Smiley, Maria Dimarchi, Joseph Chabenne, Jonathan Day, James Patterson, Brian Ward
-
Patent number: 8546337Abstract: Self-assembling peptide nanoparticles (SAPN) incorporating T-cell epitopes and/or B-cell epitopes are described. The nanoparticles of the invention consist of aggregates of a continuous peptidic chain comprising two oligomerization domains connected by a linker segment wherein one or both oligomerization domains incorporate T-cell epitopes and/or B-cell epitopes within their peptide sequence. These nanoparticles are useful as vaccines and adjuvants.Type: GrantFiled: January 29, 2009Date of Patent: October 1, 2013Assignee: Alpha-O-Peptides AGInventor: Peter Burkhard
-
Publication number: 20130252905Abstract: Provided is a multimeric peptide comprising at least two peptide monomers linked to one another, each of the at least two peptide monomers comprising at least 6 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO: 1, wherein the at least two peptide monomers are each no longer than 30 amino acids, wherein the multimeric peptide is capable of reducing binding of Placenta Immunomodulatory Factor (PLIF) to human leukocytes.Type: ApplicationFiled: March 10, 2013Publication date: September 26, 2013Applicant: Ramot at Tel-Aviv University Ltd.Inventor: Chaya MOROZ
-
Patent number: 8541377Abstract: The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.Type: GrantFiled: July 11, 2008Date of Patent: September 24, 2013Assignee: Florida Gulf Coast UniversityInventors: Scott F. Michael, Sharon Isern, Robert Garry, Ram Samudrala, Joshua Costin, Ekachai Jenwitheesuk
-
Publication number: 20130243824Abstract: An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations.Type: ApplicationFiled: February 20, 2013Publication date: September 19, 2013Applicants: ONO PHARMACEUTICAL CO., LTD.Inventors: Ono Pharmaceutical Co., Ltd., Yasuhiko Tabata
-
Publication number: 20130244933Abstract: The present invention relates to a (poly)peptide or a peptidomimetic thereof having the biological activity of Conkunitzin-S1, wherein said (poly)peptide is selected from (a) a polypeptide comprising or having the amino acid sequence of SEQ ID NO: 1; (b) a polypeptide having at least 85% sequence identity to SEQ ID NO:1; or (c) a fragment of a) or b); wherein said (poly)peptide or peptidomimetic specifically modulates the activity of a channel having the activity of a Kv1.7 containing channel, for the treatment or prevention of metabolic diseases or conditions, or secondary diseases or conditions related to said metabolic diseases or conditions.Type: ApplicationFiled: April 8, 2013Publication date: September 19, 2013Applicants: Universitat zu Lubeck, Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventors: Heinrich Terlau, Rocio Finol-Urdaneta, Stefan Becker, Walter Raasch
-
Patent number: 8536135Abstract: The present invention is related to methods of generating adaptive biochemical signatures in live cells and the use of said signatures to identify diagnostic and therapeutic modalities for human disease. The methods described herein comprise contacting a provocative agent to live cells and measuring and analyzing adaptive readouts. The methods of the invention may be used for therapeutic or diagnostic purposes.Type: GrantFiled: February 25, 2011Date of Patent: September 17, 2013Assignee: Ontherix, Inc.Inventor: Desmond Mascarenhas
-
Publication number: 20130237484Abstract: The present invention relates to a novel human-derived cell permeable peptide-bioactive peptide conjugate and the use thereof. According to the present invention, cationic cell permeable peptides derived from human bone morphogenetic protein-4 have no toxicity and immuno-genicity and thus exhibit high stability as compared to viral peptide delivery vehicles, and can transport cell impermeable material into cells and into an organism without any damage to cell or material, thereby significantly increasing target gene expression. In addition, the peptide may be applied to clinical use without having to undergo a large number of processes and mass-produced, such that the present invention may be useful in the development of a drug delivery system and treatment technologies using said peptide.Type: ApplicationFiled: April 25, 2011Publication date: September 12, 2013Applicants: Nanao Intelligent Biomedical Engineering Corporation Co., Ltd., Seoul National University R&DB FoundationInventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee, Jin Sook Suh
-
Publication number: 20130236509Abstract: The invention relates to a biodegradable microparticle having a diameter between 0.2 and 3.5 micrometer and comprising a pharmaceutically effective amount of at least one small heat-shock protein that induces IL-10 production in macrophages, said small heat-shock protein comprising an amino acid sequence identity of at least 50% to any of the sequences listed as SEQ ID NOs: 1 and 12-26.Type: ApplicationFiled: July 14, 2011Publication date: September 12, 2013Applicant: DELTA CRYSTALLON B.V.Inventor: Johannes Maria Van Noort
-
Publication number: 20130237476Abstract: The application provides synthetic peptide conjugates capable of targeting and causing ablation of adipose tissue in mammal comprising at least one targeting peptide and at least one therapeutic peptide. The synthetic peptide conjugates are envisaged to have decreased physiological toxicity and/or enhanced in situ cytotoxicity compared to the peptide CKGGRAKDC-GG-D(KLAKLAKKLAKLAK) (SEQ ID NO: 2).Type: ApplicationFiled: March 5, 2013Publication date: September 12, 2013Applicant: ABLARIS THERAPEUTICS INC.Inventor: James F. HULVAT
-
Patent number: 8530420Abstract: A method for treating and/or inhibiting arthritis is provided. The method includes administering an effective amount of a composition including a parathyroid hormone and a pharmaceutically acceptable carrier or salt to a subject with arthritis. Additionally, a method for inhibiting and/or rescuing terminal differentiation of cells is also provided.Type: GrantFiled: December 16, 2008Date of Patent: September 10, 2013Assignee: Kaohsiung Medical UniversityInventors: Mei-Ling Ho, Gwo-Jaw Wang, Je-Ken Chang, Yin-Chih Fu, Chung-Hwan Chen
-
Publication number: 20130231280Abstract: The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Enho1 by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Enho1 protein. Additionally, the expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by ENHO1 adenoviral treatment in Lepob/Lepob mice.Type: ApplicationFiled: March 26, 2013Publication date: September 5, 2013Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Andrew A. BUTLER, James L. TREVASKIS
-
Patent number: 8524672Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.Type: GrantFiled: August 19, 2011Date of Patent: September 3, 2013Assignee: Biogen Idec MA Inc.Inventors: Christine M. Ambrose, Jeffrey S. Thompson
-
Patent number: 8524862Abstract: The present invention refers to muteins of the C5a anaphylatoxin (C5a) which are C5a receptor antagonists, to nucleic acid molecules comprising a nucleotide sequence encoding such muteins of C5a anaphylatoxin, to host cells containing a nucleic acid molecule comprising a nucleotide sequence encoding such muteins of the C5a anaphylatoxin as well as to a pharmaceutical composition comprising a mutein of the C5a anaphylatoxin acting as a C5a receptor antagonists. A mutein of the invention is a C5a receptor antagonist wherein the amino acid residue naturally occurring at sequence position 69 is mutated.Type: GrantFiled: March 19, 2002Date of Patent: September 3, 2013Assignee: Cincinnati Children's Hospital Medical CenterInventors: Magnus Otto, Jörg Köhl
-
Publication number: 20130224285Abstract: The present invention presents new insights in the mechanism of action of the estrogen receptor alpha in breast cancer cells and provides means and tools for modulating said mechanisms of action, thereby influencing the proliferation of estrogen-positive cells such as cancer cells.Type: ApplicationFiled: October 13, 2011Publication date: August 29, 2013Applicants: Universite Libre de Buxelles, UNIVERSITE PIERRE ET MARIE CURIE - UPMC, CNRS, UNIVERSITY OF CRETE - SCHOOL OF MEDICINEInventors: Dominique Gallo, Guy LeClercq, Iman Haddad, Joelle Vinh, Elias Castanas, Marilena Kampa, Vasiliki Pelekanou, Yves Jacquot
-
Patent number: 8518892Abstract: The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Enho1 by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Enho1 protein. Additionally, the expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by ENHO1 adenoviral treatment in Lepob/Lepob mice.Type: GrantFiled: August 2, 2010Date of Patent: August 27, 2013Assignee: Board of Supervisors of Louisiana State University and Agricultural Mechanical CollegeInventors: Andrew A. Butler, James L. Trevaskis
-
Patent number: 8518412Abstract: The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.Type: GrantFiled: September 16, 2010Date of Patent: August 27, 2013Assignee: Senju Pharmaceutical Co, Ltd.Inventors: Takeshi Nakajima, Tomoko Nakajima, Mitsuyoshi Azuma
-
Patent number: 8518871Abstract: The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.Type: GrantFiled: October 5, 2011Date of Patent: August 27, 2013Assignee: The Regents of the University of CaliforniaInventors: Tracy Hsu, Samir M. Mitragotri
-
Patent number: 8518894Abstract: The present invention provides for novel peptides derived from human milk. In aspects of the invention, the peptides are capable, individually or in combination, of evoking an antioxidative stress response, immunomodulation, anti-inflammatory response and anti-pathogenic response. As such the peptides of the invention may be used in food supplements, milk substitutions, infant formula., mother's milk, parenteral nutrition solutions, cell/tissue/organ storage and perfusion solutions and pharmaceutical formulations.Type: GrantFiled: June 1, 2010Date of Patent: August 27, 2013Inventors: Kenneth James Friel, Apollinaire Tsopmo
-
Patent number: 8518893Abstract: It is provided a pharmaceutical composition stably containing ghrelin or its derivative, which is an endogenous growth hormone secretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R), comprising a aqueous solution containing the ghrelins having pH range of 2 to 7, wherein the aqueous solution having pH range of 2 to 7 is a buffer solution, especially, glycine hydrochloride buffer, acetate buffer, citrate buffer, lactate buffer, phosphate buffer, citric acid-phosphate buffer, phosphate-acetate-borate buffer or phthalate buffer, and the concentration of the ghrelins in the solution is from 0.03 nmol/mL to 6 ?mol/mL.Type: GrantFiled: March 6, 2012Date of Patent: August 27, 2013Assignee: Asubio Pharma Co. Ltd.Inventors: Yoshiharu Minamitake, Masaru Matsumoto
-
Patent number: 8513193Abstract: Provided herein are compositions and methods related to promoting protection or repair of articular cartilage and/or musculoskeletal soft tissue by contacting the cartilage, tissues or cellular components thereof with a parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) receptor agonist or releasing factor.Type: GrantFiled: October 13, 2009Date of Patent: August 20, 2013Assignee: University of RochesterInventors: Randy N. Rosier, Michael J. Zuscik, Erik Sampson, Susan V. Bukata, J. Edward Puzas, Hani Awad
-
Patent number: 8513198Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.Type: GrantFiled: September 14, 2012Date of Patent: August 20, 2013Assignee: Jazz Pharmaceuticals International LimitedInventors: David J. Ellis, George P. Miljanich, David E. Shields
-
Patent number: 8513188Abstract: This invention relates to the use of a cyclic compound of formula (I) wherein A, B independently in each occurrence is alkane-i,j-diyl having k carbon atoms, i and independently j being less than or equal k and k being selected from 1 to 10, wherein said alkane-i,j-diyl (i) may comprise one or more double bonds; (ii) is optionally substituted; and/or (iii) comprises a cycle, wherein the total number of cycles being cyclic sugars in said compound is selected from 0 to 4 and is less than p·(n+m); X,Y independently in each occurrence is a biocompatible functional group comprising at least one oxygen atom or two sulphur atoms; n, m independently of each other are selected from 0 to 20; p is selected from 1 to 10; n+m is equal or greater than 1; and p·(n+m) is selected from 3 to 30; wherein said compound is capable of forming a complex with a protonated primary and/or protonated secondary amino group and/or a protonated guanidinium group for the manufacture of a pharmaceutical or diagnostic composition.Type: GrantFiled: September 27, 2007Date of Patent: August 20, 2013Inventor: Paolo Botti
-
Patent number: 8513201Abstract: The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.Type: GrantFiled: June 7, 2011Date of Patent: August 20, 2013Assignee: Invion LimitedInventors: Dean Jason Naylor, Barbara Jane Johnson, Caroline Amanda Dobbin, Christopher Bruce Howard, Linda Allison Ward
-
Patent number: 8512709Abstract: An object of the invention is to provide a peptide based on a sequence of an amyloid ? peptide that may allow for induction of enhanced immune response and is safe and efficacious for prophylaxis and treatment of Alzheimer disease. An amyloid ? peptide or a portion thereof with addition or insertion of cysteine or a cysteine analogue, and a method for enhancing immune response to amyloid ? using said peptide, a medicament for prophylaxis and treatment of Alzheimer disease using said amyloid ? peptide that induces an enhanced immune response, and a DNA vaccine comprising a gene coding for an amyloid ? peptide or a sequence derived from an amyloid ? peptide with addition or insertion of cysteine or a cysteine analogue, as expected to be similarly efficacious.Type: GrantFiled: October 16, 2009Date of Patent: August 20, 2013Assignee: The Chemo-Sero-Therapeutic Research InstitueInventors: Junichi Matsuda, Kazuyoshi Kaminaka, Chikateru Nozaki